Axxess Pharma Inc. is a specialty pharmaceutical company headquartered in Markham, Ontario. The company was founded by Everett Sequeira who partnered with Dr. Ron Porter. Together, they have successfully developed commercial, scientific and regulatory components for an efficient pharmaceutical and diagnostic organization. Since 1997, Axxess Pharma has marketed and distributed various pharmaceutical products and diagnostic medical devices. Products are obtained through acquisition, licensing and distributorship arrangements and include the following:Axxess Pharma acquired and owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally; Axxess has licensed Monurol a single dose antibiotic, specific treatment for Urinary track infections with Zambon SPA Switzerland. And exclusive license for marketing, and distribution of Trans dermal patches, and cosmetic masks and patches with Caleb Pharma.
MPM manufactures quality wound care products that meet the challenge of wound healing. MPM has marketed and sold its wound care products worldwide since 1992. MPM's quality products include hydrogel saturated gauze pads; wound cleansers, including an Antiseptic Wound Cleanser; composite dressings; bordered gauze dressings; hydrocolloids foam dressings; hydrogels; calcium alginates; moisture barrier and anti-fungal cream. Below are a few of MPM's proprietary products.
Wex Pharmaceuticals Inc. (WEX) is engaged in the discovery, development, manufacture and commercialization of drug products for the management of pain. The Company’s platform technology is build upto Tetrodotoxin (TTX), a naturally occurring sodium channel blocking compound found primarily in the puffer fish or blowish. In addition the Company owns and operates a drug manufacturing facility in Nanning, China. This facility manufactures TTX for use by it in its clinical trials. (Source: ARS)
Medical Developments International Limited (MDI) is a leading Australian healthcare company in pain relief and respiratory medicine. MDI has a range of products for pain management, asthma, oxygen delivery and veterinary use. MDI's aim is to commercialise these products internationally. MDI is based in Australia and consists of three major business divisions:
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. We have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last ten years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. As a result, we are now positioned with: a strong portfolio of internal development projects, principally in the areas of gastroenterology, hepatology, incontinence and pain management an extensive sales and marketing organisation an established manufacturing base In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion. We have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, product registration or manufacturing resources which our partners require. We brought our lead product, Movicol®, to market from inception within three years, demonstrating the clear benefits which our focused product development strategies can deliver. In the years ahead Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS,s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. IDDS has three late stage product candidates in clinical development: DylojectÔ, RylomineÔ and PMI-150. The company believes the addressable market for our product candidates is approximately $3 billion per year.
IOMED is in the business of developing, manufacturing, and marketing proprietary products used in the site-specific, non-invasive administration of soluble salts or other drugs into the body for medical purposes. IOMED's active drug delivery systems employ iontophoresis as a non-invasive method of enhancing and controlling the transport of water-soluble ionic drugs into and through the skin and other body tissues using a low-level electrical current. IOMED's products are used in situations when it is advisable to avoid the pain that may accompany needle insertion and drug injection, to minimize the infiltration of carrier fluids, and/or to avoid the damage caused by needle insertion when tissue is traumatized. Companion80 electrode, IOGEL electrode, TransQFlex electrode, OptimA electrode, TransQE electrode, Numby Stuff electrode
ZARS Pharma is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs using our proprietary drug delivery technologies, primarily in the area of pain management. We have developed a portfolio of proprietary products and product candidates based on our Controlled Heat-Assisted Drug Delivery (CHADDÔ) technology and our cream technologies (Peel and DuraPeelÔ) that transform, or phase-change, from an initial liquid phase to a solid phase during application.
Elan Pharmaceuticals, Inc. is a wholly-owned subsidiary of Elan Corporation, plc (NYSE: ELAN). Elan is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges.
http://www.javelinpharmaceuticals.com
Javelin Pharmaceuticals, Inc. (Javelin) is a specialty pharmaceutical company that applies technologies to develop new drugs and improved formulations of existing drugs that target medical need in the pain management market. The Company's product candidates are focused on treating a variety of pain disorders ranging from acute and episodic moderate-to-severe pain associated with cancer pain, post-operative pain, post-trauma pain, such as orthopedic injury pain, procedural pain and burn pain. Javelin has three late stage product candidates in clinical development: Dyloject (injectable diclofenac), PMI-150 (intranasal ketamine) and Rylomine (intranasal morphine). Dyloject, PMI-150 and Rylomine has completed the Phase II product development stage based upon the United States regulatory classification. The existing formulations of these parent drugs, including oral diclofenac, oral and injectable morphine and injectable ketamine are prescription medications. (Source: 10-K)
Arakis is a wholly owned subsidiary of Sosei whose remit is to provide benefit to patients and value to shareholders by discovering, developing and commercialising innovative medicinal products based on established drugs and drug templates. Its chosen therapeutic areas are inflammatory disease and pain. The risks of taking a New Chemical Entity from concept to market are high; it can take over 10 years and costs in excess of £300 million. Arakis' approach, based on identifying new indications or uses for established drugs or drug templates, reduces the risk in the following manner: the pharmacology and safety of the drug is already well understood it is possible to bridge to existing data early proof-of-principle in man can be established the API is available or can be manufactured quickly, so minimising process research and development expenditure. As a consequence of its business model, Arakis has efficiently developed (both in terms of time and cost) a late stage clinical pipeline. Arakis was founded in March 2000 and raised over £49 million in three private equity funding rounds. The company is based at Chesterford Research Park, south of Cambridge, UK and currently has 38 employees.
Panacea Biotec Ltd., established in 1984, is a health management company involved in research, production and marketing of pharmaceuticals, vaccines and biotechnology products. Located in New Delhi, India, the Company employs an experienced, seasoned and dedicated workforce of 2,700 highly trained and skilled individuals who oversee, manage and facilitate its daily operations. Presently, the Company generates an annual revenue of $ 200 million. Dr. Jain serves a Joint Managing Director for Panacea Biotec Ltd. Providing the strategic, visionary leadership, management and guidance, he is responsible for marketing and research and development. Dr. Jain is also on the Board of Directors. His broad expanse of experience and qualifications in biotechnology enables him to efficiently handle his divergent duties. Sharing ideas and techniques in an enthusiastic and persuasive manner, he provides the most practical and comprehensive solutions to keep the company out in front of the industry. Utilizing outstanding analytical skills and an exceptional knowledge of science, he fortifies policies and strategies that contribute to the Company's overall record of success and maintain its superlative legacy of excellence. Encouraging a culture which upholds the highest possible autarky, quality and transparency, he has gained the confidence and respect of his colleagues and peers and trust of clients in the services rendered by the Company. A seasoned professional, Dr. Jain utilizes expert judgment and creativity in the analysis of complex issues involving data from multiple sources and variables. Reflecting professionalism, experience, integrity, commitment and perseverance, Dr. Jain plans to remain in his current role and continue growing and expanding with the company.
http://www.sanofi-synthelabo.com
Sanofi-Synthelabo is a major global research-based pharmaceutical group with 32,500 employees in more than 100 countries and consolidated sales of over euro 8 billion in 2003. With an R&D portfolio of 55 compounds in development, Sanofi-Synthelabo is focused on a core group of four therapeutic areas: cardiovascular disease and thrombosis; diseases of the central nervous system; internal medicine; and oncology.
Cephalon, Inc. is an international biopharmaceutical company engaged in the discovery, development and marketing of products to treat human diseases. The Company’s focuses its efforts in four core therapeutic areas: central nervous system (CNS) disorders, pain, cancer and addiction. In addition to conducting an active research and development program, it markets seven products in the United States and number of products in countries throughout Europe. The Company’s principal product is PROVIGIL (modafinil) Tablets (C-IV), which comprised approximately 49% of its total consolidated net sales during the year ended December 31, 2007, of which approximately 94% was in the United States market. In June 2007, the Company announced that it has received approval from FDA to market NUVIGIL (armodafinil) Tablets (C- IV).
Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. Biovail has a portfolio of drug-delivery technologies includes controlled release, enhanced absorption, rapid absorption, taste masking, and oral disintegration technologies, among others. In September 2008, Biovail acquired Prestwick Pharmaceuticals, Inc., a company that holds the Canadian and United States rights to Xenazine (tetrabenazine tablets).
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory